Everything below concerns bremelanotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
== Education == Bry received her bachelor's degree in Genetics and Development from Cornell University, then entered the Medical Scientist Training Program at Washington University School of Medicine in St. Louis. She was the first microbiology graduate student of Dr. Jeffrey I. Gordon and used her background in microbiology and microbial genetics to develop novel systems for studying host-microbial cross-talk within the gastrointestinal tract. She was awarded her MD and a PhD in Molecular Microbiology and Pathogenesis in 1998. She subsequently entered the residency program in Clinical Pathology at Brigham and Women's Hospital. While in her second year of the residency program, she was awarded a Howard Hughes Research Fellowship for Physicians to pursue a postdoctoral fellowship in molecular immunology in the laboratory of Dr. Michael B. Brenner at Brigham and Women's Hospital.
Noroxycodone is the major metabolite of the opioid analgesic oxycodone. It is formed from oxycodone in the liver via N-demethylation predominantly by CYP3A4. Noroxycodone binds to and activates the μ-opioid receptor (MOR) similarly to oxycodone, although with one-third of the affinity of oxycodone and 5- to 10-fold lower activational potency. However, although a potent MOR agonist, noroxycodone poorly crosses the blood-brain-barrier into the central nervous system, and for this reason, is only minimally analgesic in comparison.
== Further reading == Adams, Billy. Ewan McGregor: The Unauthorized Biography. Overlooks Press, 1999. ISBN 0-87951-704-2 Bassom, David. Ewan McGregor: An Illustrated Story. Hamlyn, 1999. ISBN 0-600-59653-2 Jones, Veda Boyd. Ewan McGregor. Facts on File Inc., 1999. ISBN 0-7910-5501-9 Nickson, Chris. Ewan McGregor: An Unauthorized Biography. Macmillan, 1999. ISBN 0-312-96910-4 Pendreigh, Brian. Ewan McGregor. Thunder's Mouth Press, 1999. ISBN 1-56025-239-1 Robb, Brian J. Ewan McGregor: From Junkie to Jedi. Plexus, 1999. ISBN 0-85965-276-9
the alternation of late wood and early wood increments within the annual ring; the influence of wood rays on the radial direction; the features of the cell wall structure such as microfibril angle modifications and pits; the chemical composition of the middle lamella. Wood drying may be described as the art of ensuring that gross dimensional changes through shrinkage are confined to the drying process. Ideally, wood is dried to that equilibrium moisture content as will later (in service) be attained by the wood. Thus, further dimensional change will be kept to a minimum. It is probably impossible to completely eliminate dimensional change in wood, but elimination of change in size may be approximated by chemical modification. For example, wood can be treated with chemicals to replace the hydroxyl groups with other hydrophobic functional groups of modifying agents. Among all the existing processes, wood modification with acetic anhydride has been noted for the high anti-shrink or anti-swell efficiency (ASE) attainable without damage to wood. However, acetylation of wood has been slow to be commercialised due to the cost, corrosion and the entrapment of the acetic acid in wood. There is an extensive volume of literature relating to the chemical modification of wood. Drying timber is one method of adding value to sawn products from the primary wood processing industries.
Sources: en.wikipedia.org
== Synthetic MSH == Synthetic analogues of α-MSH have been developed for human use. Two of the better known are afamelanotide (melanotan I) in testing by Clinuvel Pharmaceuticals and bremelanotide by Palatin Technologies. Others include modimelanotide and setmelanotide.
{\displaystyle {\begin{array}{lll}\Delta G_{\text{bind}}=-RT\ln K_{\text{d}}\\[1.3ex]K_{\text{d}}={\dfrac {[{\text{Ligand}}][{\text{Receptor}}]}{[{\text{Complex}}]}}\\[1.3ex]\Delta G_{\text{bind}}=\Delta G_{\text{desolvation}}+\Delta G_{\text{motion}}+\Delta G_{\text{configuration}}+\Delta G_{\text{interaction}}\end{array}}}
Likewise, in eukaryotes the maintenance of telomeres involves copying of an RNA template that is a constituent part of the telomerase ribonucleoprotein enzyme. Another cellular organelle, the vault, includes a ribonucleoprotein component, although the function of this organelle remains to be elucidated.
In the famous Urey-Miller experiment, the passage of an electric arc through a mixture of methane, hydrogen, and ammonia produces a large number of amino acids. Since then, scientists have discovered a range of ways and components by which the potentially prebiotic formation and chemical evolution of peptides may have occurred, such as condensing agents, the design of self-replicating peptides and a number of non-enzymatic mechanisms by which amino acids could have emerged and elaborated into peptides. Several hypotheses invoke the Strecker synthesis whereby hydrogen cyanide, simple aldehydes, ammonia, and water produce amino acids. According to a review, amino acids, and even peptides, "turn up fairly regularly in the various experimental broths that have been allowed to be cooked from simple chemicals. This is because nucleotides are far more difficult to synthesize chemically than amino acids." For a chronological order, it suggests that there must have been a 'protein world' or at least a 'polypeptide world', possibly later followed by the 'RNA world' and the 'DNA world'. Codon–amino acids mappings may be the biological information system at the primordial origin of life on Earth. While amino acids and consequently simple peptides must have formed under different experimentally probed geochemical scenarios, the transition from an abiotic world to the first life forms is to a large extent still unresolved.
== Current popular procedures == Since 2000, more products and techniques have been developed to make lip augmentation more effective and patient friendly. The relative ease of many injections is due to surgeons using tiny 30 and 31 gauge (about as thick as a dozen human hairs) needles that are used to inject the very sensitive lips. Nonetheless, topical anesthesias are often used for lip augmentation procedures. Some of these new techniques and substances include:
Sources: en.wikipedia.org
== External links == Indium Archived 2023-03-13 at the Wayback Machine at The Periodic Table of Videos (University of Nottingham) Reducing Agents > Indium low valent Archived 2023-07-09 at the Wayback Machine NIOSH Pocket Guide to Chemical Hazards Archived 2015-12-08 at the Wayback Machine (Centers for Disease Control and Prevention) usgs.gov (Mineral Commodity Summaries 2025): Indium
In 2024, The Wall Street Journal reported that big AI companies have begun negotiations with the US nuclear power providers to provide electricity to the data centres. In March 2024, Amazon purchased a Pennsylvania nuclear-powered data centre for US$650 million. In September 2024, Microsoft announced an agreement with Constellation Energy to re-open the Three Mile Island nuclear power plant to provide Microsoft with 100% of all electric power produced by the plant for 20 years. Reopening the plant, which suffered a partial nuclear meltdown of its Unit 2 reactor in 1979, will require Constellation to get through strict regulatory processes which will include extensive safety scrutiny from the US Nuclear Regulatory Commission. If approved (this will be the first ever US re-commissioning of a nuclear plant), over 835 megawatts of power – enough for 800,000 homes – will be produced. The cost for re-opening and upgrading is estimated at US$1.6 billion and is dependent on tax breaks for nuclear power contained in the 2022 US Inflation Reduction Act. As of 2024, the US government and the state of Michigan have been investing almost US$2 billion to reopen the Palisades nuclear reactor on Lake Michigan. Closed since 2022, the plant was scheduled to be reopened in October 2025. After the last approval in September 2023, Taiwan suspended the approval of data centres north of Taoyuan with a capacity of more than 5 MW in 2024, due to power supply shortages. Taiwan aims to phase out nuclear power by 2025.
Evidence from the study of the pelvis and hindlimbs of Cyonasua, indicative of morphological similarities to bones of scansorial and terrestrial generalist carnivorans such as members of the genera Galictis, Meles and Arctictis, is presented by Tarquini et al. (2026). Tseng (2026) describes the first known partial skeleton of Leptarctus wortmani from the Hemphillian strata from the Rome Beds (Oregon, United States), providing evidence of morphology of the postcranial skeleton similar to those of extant badgers belonging to the genus Meles. Lopatin et al. (2026) describe a molar of a member of the genus Mellivora from the Pleistocene strata from the Tham Hai Cave, representing the first known record of Mellivorinae in Southeast Asia. A new specimen of Cernictis hesperus, providing new information on the anatomy of members of this species, is described from the (probably late Hemphillian) strata of the Pinole Tuff Formation (California, United States) by Tseng (2026). A well-preserved cranium of a Pleistocene sable is described from the Ogorokha Site (Sakha Republic, Russia) by Boeskorov et al. (2026). Sotnikova et al. (2026) report the discovery of new fossil material of large-bodied wolverines from the Pleistocene strata from the Indigirka River basin and New Siberia (Sakha Republic, Russia), and interpret their large size as likely to be physiological adaptation to the mammoth steppe environment. Rule et al.
Typhoidal Salmonellae induce their own phagocytosis by host macrophages in vivo and inhibit digestion by lysosomal action, thereby using macrophages for their own replication and causing macrophage apoptosis. Macrophages are capable of engulfing and digesting many bacteria during their life. They can die eventually due to factors including pathogenic cytotoxicity, oxidative stress, and phagocytosis-induced apoptosis. Phagocytosis-induced apoptosis results from the powerful apoptotic stimulus of consuming bacteria and is observed in (at least) macrophages and neutrophils.
== Signs and symptoms == Physical symptoms of CMRD involving the development and function of the gastrointestinal tract and nervous system typically manifest between infancy and adolescence. The symptoms of CmRD are similar to the physical symptoms of malnutrition, as the disease arises due to the poor absorption of lipids and fat-soluble nutrients such as vitamin E. For this reason, the disease is likely to be underdiagnosed by physicians. Fat-soluble nutrients are essential for growth, development, and normal bodily function. Vitamin E deficiency is especially serious, as the vitamin is necessary for proper neurological function and development. Without Vitamin E, neurons cannot operate correctly and signals from the brain are weakened. This leads to reduced muscle development and reduced muscle contraction. Symptoms that manifest in the GI tract are likely to be a consequence of both reduced absorption of fats and physiological stress imposed on enterocytes that can not shuttle fats into circulation. Additional symptoms that occur throughout the body can be attributed to the lack of sufficient lipid sources.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.